MeiraGTx Holdings Plc (MGTX)
9.89
+0.48
(+5.10%)
USD |
NASDAQ |
Oct 15, 16:00
9.67
-0.22
(-2.22%)
After-Hours: 04:43
MeiraGTx Holdings Research and Development Expense (Quarterly) : 57.83M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 57.83M |
| March 31, 2026 | 31.98M |
| December 31, 2025 | 30.81M |
| September 30, 2025 | 32.53M |
| June 30, 2025 | 33.50M |
| March 31, 2025 | 32.78M |
| December 31, 2024 | 23.68M |
| September 30, 2024 | 26.24M |
| June 30, 2024 | 34.93M |
| March 31, 2024 | 34.32M |
| December 31, 2023 | 33.67M |
| September 30, 2023 | 27.86M |
| June 30, 2023 | 19.94M |
| March 31, 2023 | 22.32M |
| September 30, 2022 | 16.86M |
| June 30, 2022 | 24.00M |
| March 31, 2022 | 23.10M |
| December 31, 2021 | 13.62M |
| Date | Value |
|---|---|
| September 30, 2021 | 21.61M |
| June 30, 2021 | 15.19M |
| March 31, 2021 | 16.71M |
| December 31, 2020 | 4.999M |
| September 30, 2020 | 4.626M |
| June 30, 2020 | 16.20M |
| March 31, 2020 | 8.083M |
| December 31, 2019 | -2.487M |
| September 30, 2019 | 4.614M |
| June 30, 2019 | 9.772M |
| March 31, 2019 | 12.98M |
| December 31, 2018 | 10.79M |
| September 30, 2018 | 8.109M |
| June 30, 2018 | 7.791M |
| March 31, 2018 | 6.927M |
| September 30, 2017 | 6.388M |
| June 30, 2017 | 5.364M |
| March 31, 2017 | 4.823M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Xencor, Inc. | 71.90M |
| UroGen Pharma Ltd. | 17.34M |
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Viking Therapeutics, Inc. | 115.75M |
| IDEAYA Biosciences, Inc. | 108.69M |